Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 12421 | 843 | 42.4 | 88% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | HEPARANASE | Author keyword | 583 | 81% | 41% | 349 |
| 2 | CANC VASC BIOL | Address | 107 | 56% | 15% | 130 |
| 3 | PI 88 | Author keyword | 21 | 73% | 2% | 16 |
| 4 | HEPARANASE INHIBITOR | Author keyword | 15 | 88% | 1% | 7 |
| 5 | HEPARANASE 1 | Author keyword | 10 | 63% | 1% | 10 |
| 6 | HEPARANASE INHIBITORS | Author keyword | 8 | 75% | 1% | 6 |
| 7 | HEPARANASE 2 | Author keyword | 6 | 100% | 0% | 4 |
| 8 | HUMAN HEPARANASE | Author keyword | 6 | 100% | 0% | 4 |
| 9 | PG545 | Author keyword | 4 | 75% | 0% | 3 |
| 10 | SHARETT | Address | 4 | 46% | 1% | 6 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | HEPARANASE | 583 | 81% | 41% | 349 | Search HEPARANASE | Search HEPARANASE |
| 2 | PI 88 | 21 | 73% | 2% | 16 | Search PI+88 | Search PI+88 |
| 3 | HEPARANASE INHIBITOR | 15 | 88% | 1% | 7 | Search HEPARANASE+INHIBITOR | Search HEPARANASE+INHIBITOR |
| 4 | HEPARANASE 1 | 10 | 63% | 1% | 10 | Search HEPARANASE+1 | Search HEPARANASE+1 |
| 5 | HEPARANASE INHIBITORS | 8 | 75% | 1% | 6 | Search HEPARANASE+INHIBITORS | Search HEPARANASE+INHIBITORS |
| 6 | HEPARANASE 2 | 6 | 100% | 0% | 4 | Search HEPARANASE+2 | Search HEPARANASE+2 |
| 7 | HUMAN HEPARANASE | 6 | 100% | 0% | 4 | Search HUMAN+HEPARANASE | Search HUMAN+HEPARANASE |
| 8 | PG545 | 4 | 75% | 0% | 3 | Search PG545 | Search PG545 |
| 9 | HEPARAN SULFATE PROTEOGLYCANS | 2 | 10% | 3% | 22 | Search HEPARAN+SULFATE+PROTEOGLYCANS | Search HEPARAN+SULFATE+PROTEOGLYCANS |
| 10 | ENDO BETA GLUCURONIDASE | 2 | 67% | 0% | 2 | Search ENDO+BETA+GLUCURONIDASE | Search ENDO+BETA+GLUCURONIDASE |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MAMMALIAN HEPARANASE | 621 | 85% | 40% | 333 |
| 2 | ENDOGLYCOSIDASE HEPARANASE | 72 | 100% | 3% | 23 |
| 3 | SULFATE PROTEOGLYCANS | 45 | 25% | 18% | 155 |
| 4 | SULFATE DEGRADATION | 45 | 90% | 2% | 19 |
| 5 | PLATELET HEPARANASE | 30 | 100% | 1% | 12 |
| 6 | INHIBITOR PI 88 | 27 | 92% | 1% | 11 |
| 7 | SUBENDOTHELIAL EXTRACELLULAR MATRIX | 19 | 25% | 8% | 66 |
| 8 | ANTISENSE MEDIATED SUPPRESSION | 18 | 89% | 1% | 8 |
| 9 | PRIMARY BREAST TUMORS | 18 | 89% | 1% | 8 |
| 10 | MATRIX DEGRADATIVE ENZYMES | 17 | 100% | 1% | 8 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Heparanase: a target for drug discovery in cancer and inflammation | 2007 | 129 | 114 | 82% |
| Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis | 2006 | 186 | 145 | 76% |
| Heparanase: busy at the cell surface | 2009 | 63 | 70 | 76% |
| Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis | 2010 | 50 | 108 | 66% |
| Heparanase involvement in physiology and disease | 2008 | 43 | 92 | 83% |
| Mammalian heparanase: what is the message? | 2007 | 100 | 175 | 67% |
| The heparanase/syndecan-1 axis in cancer: mechanisms and therapies | 2013 | 31 | 106 | 37% |
| Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate | 2007 | 75 | 102 | 72% |
| Heparanase in inflammation and inflammation-associated cancer | 2013 | 13 | 132 | 73% |
| Development of heparanase inhibitors for anti-cancer therapy | 2006 | 67 | 107 | 88% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CANC VASC BIOL | 107 | 56% | 15% | 130 |
| 2 | SHARETT | 4 | 46% | 0.7% | 6 |
| 3 | MOL ONCOGENESIS GRP | 3 | 100% | 0.4% | 3 |
| 4 | ZHONG SHAN MEN IN PATIENT | 3 | 45% | 0.6% | 5 |
| 5 | CANC VASC BIOL GRP | 3 | 28% | 1.1% | 9 |
| 6 | ONCOL AREA DEV | 3 | 60% | 0.4% | 3 |
| 7 | DRUG DESIGN GRP | 3 | 21% | 1.3% | 11 |
| 8 | BIOQUIM BIOL CELULAR GLICOCONJUGADOS | 2 | 43% | 0.4% | 3 |
| 9 | CANC MOL IMMUNOL GRP | 1 | 100% | 0.2% | 2 |
| 10 | CANC VASC | 1 | 100% | 0.2% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000181289 | SYNDECAN 1//SYNDECAN//SYNDECAN 4 |
| 2 | 0.0000124809 | HEPARAN SULFATE//OVERSULFATED CHONDROITIN SULFATE//HEPAROSAN |
| 3 | 0.0000100053 | SCHWARTZ JAMPEL SYNDROME//PERLECAN//STUVE WIEDEMANN SYNDROME |
| 4 | 0.0000099718 | SULODEXIDE//INHALED HEPARIN//POLYANIONIC CHARGE |
| 5 | 0.0000072187 | HALOFUGINONE//MRI MRS HBRC//CLUSTER PROJECT |
| 6 | 0.0000043141 | SURAMIN//HT 29 D4 CELLS//SURAMIN ANALOGUES |
| 7 | 0.0000041394 | GLYPICAN 3//GPC3//SIMPSON GOLABI BEHMEL SYNDROME |
| 8 | 0.0000039624 | LRIG1//LRIG3//LRIG2 |
| 9 | 0.0000038735 | AZ64//TROPOMYOSIN RECEPTOR KINASES//CEP 701 |
| 10 | 0.0000038501 | FRACTIONAL CLEARANCE//CHARGE SELECTIVITY//GLOMERULAR BASEMENT MEMBRANE |